Day: January 7, 2021

Increase in need for cash alternatives, development of the e-commerce industry, and availability of affordable and energy-efficient prepaid cards have boosted the growth of the EEA prepaid card market. However, lack of standardization and fraudulent attacks hinder the market growth. On the contrary, surge in the unbanked and underbanked population would open new opportunities for the market players in the future. As per the report by Allied Market Research, the EEA prepaid card industry was pegged at $182.64 billion in 2019, and is expected to reach $500.27 billion by 2027, registering a CAGR of 14.7% from 2020 to 2027. The retail segment held the largest share By end user, the retail segment dominated the market in 2019, contributing to more than half of the EEA prepaid card market, due to growing large customer base shifting from traditional...

 Geneva, Switzerland and Boston, MA – January 7, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating in the JP Morgan Virtual Healthcare Conference taking place January 11-14, 2021.  ObsEva will present on Thursday, January 14, 2021 at 7:30 a.m. Eastern Time (ET).The presentation webcast will be available in the “Investors” section of ObsEva’s website www.ObsEva.com.

MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has entered into a committed equity purchase agreement (“Purchase Agreement”) for up to $40 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.Over the 24-month term of the Purchase Agreement, the Company will have the right to direct LPC to purchase up to an aggregate amount of $40 million American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company. LPC’s maximum obligation under any single regular purchase will not exceed $2.5 million, unless both parties mutually...

Pixium Vision annonce le tirage d’une nouvelle tranche de 1,25 M€ de valeur nominale dans le cadre du contrat de financement avec ESGOParis, le 7 janvier 2021 – 07h00 CET – Pixium Vision (FR0011950641 – ALPIX), société bioélectronique qui développe des systèmes de vision bioniques innovants pour permettre aux patients ayant perdu la vue de vivre une vie  plus autonome, annonce avoir procédé à l’émission d’une nouvelle tranche d’Obligations d’un montant nominal de 1,25 million d’euros correspondant à 125 Obligations, en demandant à European Select Growth Opportunities Fund (« ESGO »), investisseur basé aux Etats-Unis et spécialisé dans la santé, d’exercer 125 Bons d’Emission sur les 625 Bons d’Emission restants.Cette annonce intervient conformément aux dispositions de l’accord avec ESGO relatif à un financement pour un montant nominal...

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) — Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its upsized public offering of 2,208,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share. The aggregate gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude. In addition, Prelude has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of voting common stock at the public offering price, less underwriting discounts and commissions. The offering is expected...

Lenexa, KS, Jan. 06, 2021 (GLOBE NEWSWIRE) — Digital Ally, Inc. (NASDAQ: DGLY) (the “Company”), which develops, manufactures and markets advanced video recording products and other critical safety products for law enforcement, emergency management, fleet safety and security, announced that, due to market conditions, it has elected not to proceed at this time with its previously announced plans to pursue an underwritten public offering of its common stock.Digital Ally remains well capitalized and expects that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements until at least the end of 2021.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share. Harpoon Therapeutics expects that the gross proceeds from the sale of the shares will be approximately $100.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon Therapeutics. In addition, Harpoon Therapeutics has granted the underwriters in the offering a 30-day option to purchase up to 882,352 additional shares of common stock at the public offering price. The offering is expected to close on January 11, 2021, subject to customary closing conditions.Harpoon Therapeutics plans to use the net proceeds of the offering, together...

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Generation Bio, are expected to be approximately $196.0 million, excluding any exercise of the underwriters’ option to purchase additional...

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the pricing of an underwritten global offering of 6,000,000 registered shares (the New Shares) (including shares in the form of American Depositary Shares, or ADSs) at a public offering price of approximately CHF1.47 per share or $10.00 per ADS. Each ADS represents the right to receive six shares of Addex.  The aggregate gross proceeds from the offering are expected to be $10.0 million, before deducting the underwriting discounts and commissions and offering expenses payable by Addex. The offering is expected to close on or about January 11, 2021, subject to satisfaction of customary closing conditions.H.C. Wainwright &...

VANCOUVER, British Columbia, Jan. 06, 2021 (GLOBE NEWSWIRE) — AZINCOURT ENERGY CORP. (“Azincourt” or the “Company”) (TSX.V: AAZ, OTC: AZURF), is pleased to announce that it will offer up to 30,000,000 flow-through units (each, an “FT Unit”) by way of non-brokered private placement at a price of $0.05 per FT Unit for gross proceeds of up to $1,500,000.  Each “FT Unit” will be comprised of one common share, and one common share purchase warrant exercisable to acquire an additional common share at a price of $0.07 for a period of sixty months. In connection with the placement, the Company anticipates a single institutional investor will acquire up to 28,000,000 FT Units.The gross proceeds from the placement will be used to fund Canadian Exploration Expenses (within the meaning of the Income Tax Act (Canada)) which shall qualify as...